Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · IEX Real-Time Price · USD
84.79
-0.06 (-0.07%)
At close: Jul 2, 2024, 4:00 PM
83.14
-1.65 (-1.95%)
After-hours: Jul 2, 2024, 4:03 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for LGND stock have an average target of 116.33, with a low estimate of 95 and a high estimate of 144. The average target predicts an increase of 37.20% from the current stock price of 84.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LGND stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +12.04% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $144 | Strong Buy | Reiterates | $144 | +69.83% | Jun 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $144 | Strong Buy | Reiterates | $144 | +69.83% | May 8, 2024 |
| Benchmark | Benchmark | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +12.04% | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $144 | Strong Buy | Reiterates | $144 | +69.83% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
140.55M
from 131.31M
Increased by 7.03%
Revenue Next Year
163.81M
from 140.55M
Increased by 16.55%
EPS This Year
4.73
from 2.94
Increased by 60.98%
EPS Next Year
5.65
from 4.73
Increased by 19.47%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 148.4M | 178.5M | 246.8M | 248.1M | 305.1M |
| Avg | 140.6M | 163.8M | 217.8M | 241.0M | 296.4M |
| Low | 131.3M | 150.7M | 188.3M | 231.5M | 284.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 13.0% | 27.0% | 50.6% | 13.9% | 26.6% |
| Avg | 7.0% | 16.5% | 33.0% | 10.6% | 23.0% |
| Low | 0.0% | 7.2% | 14.9% | 6.3% | 18.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 4.96 | 6.13 | 7.81 |
| Avg | 4.73 | 5.65 | 7.59 |
| Low | 4.41 | 5.18 | 7.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 68.6% | 29.6% | 38.2% |
| Avg | 61.0% | 19.5% | 34.2% |
| Low | 50.0% | 9.5% | 29.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.